Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Xpert® Bladder Cancer Monitor Assay Compared to Cystoscopy for the Follow-up of Patients With History of Low or Intermediate Risk Non-muscle-invasive Bladder Cancer (NMIBC): an Observational Prospective International Multicenter Study

NCT03664258 is registered in ClinicalTrials.gov with Cepheid as lead sponsor.

NCT NCT03664258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03664258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Xpert® Bladder Cancer Monitor Assay Compared to Cystoscopy for the Follow-up of Patients With History of Low or Intermediate Risk Non-muscle-invasive Bladder Cancer (NMIBC): an Observational Prospective International Multicenter Study
Lead sponsor
Cepheid
Phase
Observational
Overall status
Completed
Start date
June 6, 2018
Completion date
January 31, 2022
Enrollment
852 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle-invasive bladder cancer